MX2022000889A - Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. - Google Patents

Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.

Info

Publication number
MX2022000889A
MX2022000889A MX2022000889A MX2022000889A MX2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A
Authority
MX
Mexico
Prior art keywords
hydroxybenzoyl
egf
amino
salt
caprylic acid
Prior art date
Application number
MX2022000889A
Other languages
English (en)
Inventor
Andreas Vegge
Betty Lomstein Pedersen
Birgitte Nissen
Kaisa Naelapää
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022000889A publication Critical patent/MX2022000889A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de las composiciones, y a su uso en medicina.
MX2022000889A 2019-08-07 2020-08-07 Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. MX2022000889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190506 2019-08-07
PCT/EP2020/072227 WO2021023855A1 (en) 2019-08-07 2020-08-07 Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
MX2022000889A true MX2022000889A (es) 2022-02-14

Family

ID=67551283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000889A MX2022000889A (es) 2019-08-07 2020-08-07 Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.

Country Status (14)

Country Link
US (1) US20220323544A1 (es)
EP (1) EP4009958A1 (es)
KR (1) KR20220046565A (es)
CN (1) CN114222581A (es)
AR (1) AR122299A1 (es)
AU (1) AU2020326265A1 (es)
BR (1) BR112022000529A2 (es)
CA (1) CA3144618A1 (es)
CO (1) CO2022000575A2 (es)
IL (1) IL289505A (es)
MX (1) MX2022000889A (es)
PE (1) PE20220486A1 (es)
TW (1) TW202120118A (es)
WO (1) WO2021023855A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240036563A (ko) * 2021-07-15 2024-03-20 노보 노르디스크 에이/에스 N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101506147B (zh) 2006-09-07 2012-03-21 霍夫曼-拉罗奇有限公司 用于制备snac（n-（8-[2-羟基苯甲酰基]-氨基）辛酸钠）的方法
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
CN103717615A (zh) 2011-06-20 2014-04-09 霍夫曼-拉罗奇有限公司 结合pcsk9的多肽及使用方法
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
US10335369B2 (en) * 2012-03-22 2019-07-02 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
MX2018008681A (es) 2016-01-13 2018-09-17 Novo Nordisk As Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
MX2018016057A (es) * 2016-06-24 2019-05-06 Hoffmann La Roche Composiciones y metodos para tratar enfermedades cardiovasculares.
US20200165313A1 (en) 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof

Also Published As

Publication number Publication date
AU2020326265A1 (en) 2022-02-03
KR20220046565A (ko) 2022-04-14
IL289505A (en) 2022-02-01
CN114222581A (zh) 2022-03-22
CO2022000575A2 (es) 2022-04-29
EP4009958A1 (en) 2022-06-15
TW202120118A (zh) 2021-06-01
CA3144618A1 (en) 2021-02-11
WO2021023855A1 (en) 2021-02-11
US20220323544A1 (en) 2022-10-13
AR122299A1 (es) 2022-08-31
BR112022000529A2 (pt) 2022-03-03
PE20220486A1 (es) 2022-04-04

Similar Documents

Publication Publication Date Title
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
MX2022004718A (es) Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
MX2022000827A (es) Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2022000889A (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2013006171A (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX2013013913A (es) Polipeptidos.
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
EA202192925A1 (ru) Твердые формы ингибитора glyt1
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2016007407A (es) Peptidos resistentes a proteasa.
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
GB2556854A (en) Cosmetic formulations
MX2021008748A (es) Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.
CO2024000581A2 (es) Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
MX2022005044A (es) Formulacion de anticuerpo que contiene crizanlizumab.
AR110548A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares